Radiopharm Theranostics (RAD) H2 2024 earnings summary

Executive summary

• Achieved significant milestones in clinical programs, including first patient dosing in two Phase 1 trials and IND approval for a brain metastases imaging agent.

• Completed a landmark A$70 million capital raise, including a strategic investment from Lantheus Holdings, strengthening financial position and supporting operations through 2026.

• Increased institutional ownership to 75%, reflecting strong investor confidence.

• Expanded joint venture with MD Anderson Cancer Center, increasing ownership to 75% and committing additional funding.

Financial highlights

• Reported a net loss of $47.95 million for FY24, up from $34.61 million in FY23, driven by increased R&D and clinical trial activity.

• Revenue from contracts was $299,228, with other income of $1.34 million, mainly from R&D tax incentives.

• Cash reserves increased to $18.58 million as of 30 June 2024, compared to $11.70 million a year earlier.

• Net assets decreased to $27.35 million from $45.58 million, primarily due to amortisation, asset sales, and increased payables.

• No dividends declared or paid for FY24.

Outlook and guidance

• Capital raised is expected to fully fund clinical programs through 2026.

• Plans to pursue a Nasdaq listing by the end of 2024 to broaden the investor base.

• Ongoing focus on advancing clinical pipeline, regulatory milestones, and global expansion.